US agency speeds up analysis of psychedelic drugs after Trump order

Agência of Alimentos and Medicamentos of Estados Unidos announced this Friday measures to accelerate the development of new treatments against serious mental illnesses. The decision follows an executive order signed by President Donald Trump last week.
The text directs the federal government to speed up access to psychedelic drugs with therapeutic potential. The FDA said it will issue national priority vouchers to three companies researching these compounds. Dois projects involve psilocybin. A third studies methylone for post-traumatic stress disorder.

Ordem executive defines new federal priority
The president signed the document on April 18. The measure requires federal agencies to facilitate research and access to psychedelics for conditions such as treatment-resistant depression, alcoholism and other serious disorders.
FDA Commissioner Marty Makary said in a statement that these medications could help address the mental health crisis in the country. The agency will use the commissioner’s voucher program to prioritize reviews. The mechanism allows review time to be reduced from months to weeks in selected cases.
Empresas who receive the voucher gain speed in the approval queue. The FDA did not reveal the names of the benefiting companies. Dois studies focus on psilocybin, the active ingredient in hallucinogenic mushrooms. One treats resistant depression. Outro addresses major depressive disorder. The third initiative uses methylone, a substance related to MDMA, against PTSD.
Psilocibina and methylone receive special attention
Pesquisas with psilocybin has been progressing in clinical trials for years. The compound has received breakthrough therapy designation in some cases by the FDA itself. Methylone also shows promising preliminary results in anxiety and stress disorders.
- Psilocibina for treatment-resistant depression
- Psilocibina for major depressive disorder
- Metilona for post-traumatic stress disorder
Esses vouchers represent the first time the national priority program has explicitly covered psychedelics. The decision does not guarantee final approval. Products still need to demonstrate safety and efficacy in studies.
Muitos psychedelics continue to be classified as Schedule I substances. Isso means high potential for abuse and no accepted medical use under current federal law. The executive order also mentions ibogaine and paves the way for compassionate use in eligible patients.
Mental Health Contexto Drives Initiative
Os Estados Unidos face high rates of depression, suicide and drug addiction. Autoridades federal authorities seek alternatives when conventional treatments fail. Especialistas has long been tracking early results from psychedelic-assisted therapies in controlled environments.
Trump’s order also directs US$50 million to partnerships between federal and state governments. The text asks the FDA and DEA to reduce regulatory barriers to research. The objective is to expand the pipeline of new medicines.
The regulatory agency plans to publish additional guidance on using the vouchers. The National Priority Voucher pilot program began last year. Ele has already benefited other products considered strategic for public health.
Impacto regulatory and next steps
The FDA must define shorter timelines for covered companies. Full Revisões may drop to one or two months instead of the usual six to ten. Isso accelerates the arrival of therapies to market if clinical data is favorable.
Pesquisadores and companies in the sector celebrate the sign of federal support. The movement occurs in parallel with initiatives in some states that have decriminalized or regulated the use of psychedelics in therapeutic contexts. Oregon and Colorado lead these local experiments.
Casa Branca highlighted that the action seeks to save lives and treat resistant conditions. The secretary of Saúde and Serviços Humanos, Robert F. Kennedy Jr., participated in events related to the topic.
This Friday’s announcement reinforces the administration’s commitment to innovation in mental health. Autoridades monitor ongoing clinical trials. Novas updates on all three projects are expected to emerge in the coming months.
The FDA reinforced that all approvals will follow the usual standards of scientific evidence. The focus remains on protecting public health. Additional Pesquisas are still needed to define safety protocols, dosing and clinical monitoring.
Reação initial market and scientific community
Empresas of biotechnology that works with psychedelics registered positive changes in its shares after the announcement. Analistas assess that regulatory priority can attract more investment to the sector.
Grupos of patients with chronic depression follow the topic with expectation. Defensores from mental health ask that the process maintain scientific rigor. Críticos warn of risks of inappropriate use outside of medical supervision.
The regulatory agency is expected to publish more details about the criteria used to select the three projects. The voucher program includes monitoring mechanisms to prevent abuse.
Pesquisas with ibogaine also gained space in the executive order. An initial study of a metabolite of the substance was authorized for alcohol dependence. Original ibogaine has known heart risks.
Perspectivas for future approval
The road to commercialization is still long. Mesmo with accelerated review, products must complete advanced phases of testing. Dados’s efficacy in larger populations will be decisive.
The FDA will continue to require randomized, controlled trials. Monitoring for long-term side effects is mandatory. Especialistas estimate that the first approvals, if confirmed, could occur in one or two years.
The topic gains relevance amid the national debate on mental health. Recent Dados show an increase in cases of depression and anxiety after the pandemic. Novas therapeutic options are welcomed by doctors and patients.
The federal initiative signals a change in attitude towards previously marginalized compounds. The balance between innovation and security remains central to the regulatory process.






